ArticleParasitology research2025
Effect of antiserum against recombinant EGr_09888 on the in vitro development of Echinococcus granulosus protoscoleces.
Article in Parasitology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To investigate the effects of Echinococcus granulosus sensu stricto (E. granulosus s.s.) reproduction-associated protein EGr_09888 on the development of E. granulosus s.s. protoscoleces (PSCs) in vitro. SWISS-MODEL, Netphos3.1, and PyMOL bioinformatics analysis software, along with subcellular localization prediction, were used to analyze the structure, phosphorylation sites, epitopes, and distribution of the EGr_09888 protein. The recombinant plasmid pET30a-EGr_09888 was constructed for protein expression and purification, and New Zealand white rabbits were immunized with the recombinant protein. An indirect ELISA method was used to determine serum IgG levels, through Western blotting to verify immune specificity and different stages worm protein extracts EGr_09888 protein expression. The distribution of EGr_09888 in PSCs, adult worms and gravid segments was analyzed by immunofluorescence staining. PSCs cultured in vitro for 3, 6, and 10 weeks were treated with rabbit anti-EGr_09888 high-titer immune serum for 6 days and then their survival rate and the gene expression of EGr_09888 in the PSCs was analyzed. The result revealed that the EGr_09888 protein has diverse secondary-structure amino acid proportions, and its SWISS-MODEL-predicted tertiary structure is reliable, containing 54 potential phosphorylation sites. It has B- and T-cell epitopes at amino acids (aa) 25-44 and 166-185, shows immunogenic potential, and is localized mainly in the cytoplasm. Induced expression of the recombinant EGr_09888 protein (27 kDa) resulted in rabbit anti-EGr_09888 serum with a potency greater than 1:160000. Immunoblotting revealed that the rabbit anti-EGr_09888 serum could specifically bind to the recombinant EGr_09888 protein. And the expression level of EGr_09888 protein was higher in adult worm protein extracts (P ≤ 0.001), Immunofluorescence staining analysis revealed that EGr_09888 was localized mainly within the uterus of the gravid segment of E. granulosus s.s adult worms. After 6- and 10-week-old PSCs were treated with rabbit anti-EGr_09888 serum, the survival rate and relative PSC EGr_09888 expression level were significantly reduced (P < 0.0001). This study revealed that EGr_09888, a reproduction-related protein in E. granulosus s.s., has potential as a candidate vaccine for definitive hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.